Clear Search

Showing 1 result for “FAERS; Janus kinase inhibitor; Tofacitinib; pemphigus; pharmacovigilance”.

October 2023

Janus Kinase Inhibitor—Tofacitinib Associated with Pemphigus: An Analysis of the FDA Adverse Event Reporting System Data

Expert Opin Drug Saf. 2023;18:1-4 doi: 10.1080/14740338.2023.2248872 Epub ahead of print

This study presents initial data suggesting an association between the use of JAK inhibitors and pemphigus. This research used the FAERS database to investigate connections between JAK inhibitor usage and the occurrence of pemphigus as an adverse event.